

INTRODUCTION TO ATLAS



ATLAS is led by a group of expert clinicians, patient advocates, patient organisation leaders and Takeda that is focused on achieving the best possible treatment and care for all patients with intestinal failure (IF).

- ATLAS was formed in 2016 as a response to a lack of awareness and poor harmonisation of standard of care across Europe.
- The vision of ATLAS is for all IF patients in Europe to receive an equal standard of care by 2030, as documented through the improvement in reported patient outcomes.



- To turn that vision into a reality, ATLAS is working with stakeholders across Europe to:
 - increase awareness of IF
 - improve the diagnosis rate
 - facilitate the sharing of clinical excellence across borders
 - alert the scientific community to inequalities in provision of care



- Since its inception, the ATLAS Steering Committee, in collaboration with Takeda, has launched several initiatives to identify and address the urgent unmet needs of people living with IF to improve patient outcomes across Europe.
- The ATLAS programme is funded and initiated by Takeda.

Disclaimers


Intended for a global audience (outside of the US/UK).

This project is initiated and funded by Takeda.

THE INTESTINAL FAILURE LANDSCAPE IN EUROPE



 CIF/SBS-IF OR HPN PREVALENCE DATA	 NATIONAL GUIDELINES FOR CIF & SBS	 REGISTRIES (CIF/SBS-IF/HPN)	 PATIENT ORGANISATIONS (SBS/IF/HPN/HAN)
---	--	--	---




● HPN ● HPN & SBS-IF
● SBS-IF ● NO INFO

References 1-14



● CIF & SBS ● NO INFO
● SBS-IF

References 15-23



● HPN ● HPN & SBS-IF ● NO INFO
● HPN & CIF ● HPN & SBS-IF & CIF

References 24-35



● YES ● NO INFO

References 36-67

ATLAS FINDINGS

- There is a lack of clear epidemiological data. This makes it difficult for countries to know the true size of the population affected by IF and allocate the resources required to treat IF.
- Currently, some countries have no implemented national guidelines for IF care. This could be a contributing factor to variable standards of care across Europe.
- 16 European countries have no available evidence of patient registries relating to IF, making it hard to collect and share data about the IF patient care pathway.
- There is a need for more IF-specific patient groups at a national level, and European and international collaboration between those groups, to raise the IF patient voice.

Please see the following pages for references.



METHODOLOGY

Search methods and sources: Data collection and validation took place from October 2019 to April 2020 (except the search for clinical trials data, which was performed in August 2020). Sources are provided as references and include peer-reviewed academic sources, official Governmental or national/regional authority sources, and reputable online sources that are publicly accessible.

No information available (NO-INFO): For some data points, no information was available at the time the search was performed (October 2019 to April 2020 for all data points, except for search for clinical trials data, which was performed in August 2020).

References

Prevalence: **1.** Belgium. UMBRAIN, N. et al. (2019). *Clinical Nutrition*. 38, S59-S296. **2.** Czech Republic. BUDINSKA, E. et al. (2019). *Journal of Parenteral and Enteral Nutrition*. 44(1), 105-118. **3.** Denmark. JEPPESEN, P. (2014). *Journal of Parenteral and Enteral Nutrition*. 38(1), 8S-13S. **4.** France. KELLY, DG. et al. (2014). *JPEN Parenter. Enteral Nutr.* 38(4), 427-37. **5.** Germany. VON WEBSKY, M. et al. (2014). *Der Chirurg*. 85, 433-439. **6.** Ireland. BELL, A. et al. (2018). Point Prevalence of Adult Intestinal Failure in Republic of Ireland. *Irish Medical Journal*. 111(2), 688. **7.** Italy. DIAMANTI, A. et al. (2017). *Nutrients*. 9(11). **8.** Netherlands. KELLY DG et al. (2014). *JPEN Parenter Enteral Nutr.* 38(4), 427-37. **9.** Netherlands. NEELIS, E. et al. (2016). *Clinical Nutrition*. 35(1), 225-229. **10.** Poland. JEPPESEN, P. (2014). 38(1), 8S-13S. **11.** Poland. KELLY, DG. et al. (2014). *JPEN Parenter Enteral Nutr.* 38(4), 427-37. **12.** Spain. KELLY, DG. et al. (2014). *JPEN Parenter Enteral Nutr.* 38(4), 427-37. **13.** United Kingdom. KELLY, DG. et al. (2014). *JPEN Parenter Enteral Nutr.* 38(4), 427-37. **14.** United Kingdom. SMITH, T. et al. (2016). BAPEN (British Association of Parenteral and Enteral Nutrition).

National Guidelines: **15.** Belgium. BAXTER, JP. et al. (2012). *Clinical Nutrition*. 7(5), E211-214. **16.** Czech Republic. Společnost klinické výživy a intenzivní metabolické péče (SKVIMP) (2020). Doporučené postupy, Společnost klinické výživy a intenzivní metabolické péče (SKVIMP), viewed 21 August 2020 <<http://www.skvimp.cz/podklady/doporucene-postupy-guidelines/>>. **17.** Czech Republic. Společnost klinické výživy a intenzivní metabolické péče (SKVIMP) (2020). Doporučené postupy, Společnost klinické výživy a intenzivní metabolické péče (SKVIMP), viewed 21 August 2020, <<http://www.skvimp.cz/pracovni-skupiny/domaci-parentalni-vyziva/doporucene-postupy/>>. **18.** Germany. GPGE Gesellschaft für Pädiatrische Gastroenterologie und Ernährung 2018, Positionspapier Teduglutid, Gesellschaft für Pädiatrische Gastroenterologie und Ernährung, viewed on 21 August 2020 <https://static1.squarespace.com/static/55db8048e4b089b9924893b3/t/5aa7d01c83025af3fa1a8df/1520947443695/1803_Positionspapier_GPGE_Teduglutid_Konsens.pdf>. **19.** Germany. LAMPRECHT, G. et al. (2014). Aktuelle Ernährungsmedizin, 39(02), e57-e71. **20.** Germany. Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (2019), Die Zukunft liegt im gesunden Kinderbauch, Gesellschaft für Pädiatrische Gastroenterologie und Ernährung, viewed 21 August 2020, <<https://www.gpge.eu/leitlinien/>>. **21.** Spain. SEGHPN Sociedad Española de Gastroenterología Pediátrica, viewed 21 August 2020 <https://www.seghnp.org/documentos?field_tipo_de_documento_target_id_1=1>. **22.** Sweden. ELLEGÅRD, L. et al. (2016), Tarmsvikt - Handläggning och behandling, Svensk Gastroenterologisk Förening, viewed 21 August 2020, <<https://svenskgastronterologi.se/wp-content/uploads/2017/06/2016-Tarmsvikt.pdf>>. **23.** United Kingdom. British Intestinal Failure Alliance (2018), Use of peptide growth factors for adult patients with intestinal failure, British Association for Parenteral and Enteral Nutrition, viewed 21 August 2020, <<https://www.bapen.org.uk/pdfs/bifa/position-statements/use-of-peptide-growth-factors-for-adult-patients-with-intestinal-failure-draft.pdf>>.

Registries: **24.** Belgium. UMBRAIN, N. et al. (2019). *Clinical Nutrition*. 38, S59-S296. **25.** Czech Republic. TESINSKY, P. et al. (2015). *Clinical Nutrition*. 34, S201. **26.** Denmark. BRANDT, C. et al. (2016). *Journal of Parenteral and Enteral Nutrition*. 1-8. **27.** Denmark. FUGSLANG, K. et al. (2020). *Nutrition in Clinical Practice*. 0, 1-9. **28.** Ireland. RICE, N. et al. (2013). *IrSPEN Special Report*. 1, 5-39. **29.** Italy. LEZO, A. et al. (2018). *Hepatology and Nutrition (SIGENP)*. *Nutrients*. 10(9), 1311. **30.** Netherlands. NEELIS, E. et al. (2016). *Clinical Nutrition*. 35(1), 225-229. **31.** Netherlands. NABER, AH.J. et al. (2005). *Ned Tijdschr Geneesk.* 149(8), 385-390. Viewed 21 August 2020, <<https://www.nvtg.nl/system/files/publications/2005103850001a.pdf>>. **32.** Norway. Biobank Norway, Norwegian health data, viewed 21 August 2020, <<https://bbmr.no/health-data>>. **33.** Spain. Spanish Rare Diseases Registries Research Network Instituto de Salud Carlos III, viewed 21 August 2020, <<https://spainrdr.isciii.es/Paginas/default.aspx>>. **34.** Spain. WANDENBERGHE, C. et al. (2018). *Clinical Nutrition*. 35(6), 1491-1496. **35.** United Kingdom. British Artificial Nutrition Survey 2020, BANS Reports, British Association for Parenteral and Enteral Nutrition, viewed 21 August 2020, <<https://www.bapen.org.uk/resources-and-education/publications-and-reports/bans/>>.

Patient Organisations: **36.** Austria. Die-chronischen-experten. 2020. Homepage. Viewed 21 August 2020, <<https://www.die-chronischen-experten.at/>>. **37.** Austria. Österreichische Morbus Crohn / Colitis Ulcerosa Vereinigung. 2020. Homepage. Viewed 21 August 2020, <<https://www.oemccv.at/>>. **38.** Belgium. Hello TPN. 2019. Homepage. Viewed 21 August 2020, <<https://www.vzwhellotpn.be/>>. **39.** Belgium. La Vie par un Fil. 2020. Homepage. Viewed 21 August 2020, <<http://www.lavieparunfilbelgique.be/index.php>>. **40.** Bulgaria. Национална пациентска организация. 2020. Homepage. Viewed 21 August 2020, <<http://www.npo.bg/>>. **41.** Croatia. Hrvatsko udruženje za Crohnovu bolest i Ulcerozni Kolitis. 2015. Homepage. Viewed 21 August 2020, <<https://hucuk.hr/>>. **42.** Croatia. Udruga oboljelih od Crohnove bolesti i ulceroznog kolitisa. 2019. Homepage. Viewed 21 August 2020, <<http://www.colonos.hr/>>. **43.** Czech Republic. Život bez střeva. 2020. Homepage. Viewed 21 August 2020, <<https://zivotbezstreva.cz/>>. **44.** Denmark. HPN-föreningen - en frivillig patientorganisation. 2020. Homepage. Viewed 21 August 2020, <<https://hpndk/>>. **45.** Denmark. Colitis-Crohn Foreningen. 2020. Homepage. Viewed 21 August 2020, <<https://ccf.dk/>>. **46.** Estonia. Eesti Põletikulise Soolehaiguse Selts. 2020. Homepage. Viewed 21 August 2020, <<http://www.ibd.ee/>>. **47.** Finland. Crohn ja Colitis. 2020. Homepage. Viewed 21 August 2020, <<https://crohnjacolitis.fi/>>. **48.** France. La Vie par un Fil. 2020. Homepage. Viewed 21 August 2020, <<https://www.lavieparunfil.com/>>. **49.** Germany. Selbsthilfe Kurzdarmsyndrom. 2020. Homepage. Viewed 21 August 2020, <<http://selbsthilfe-kurzdarmsyndrom.de/>>. **50.** Germany. Kinder in Schwieriger Ernährungssituation. 2020. Homepage. Viewed 21 August 2020, <<http://kise-ev.de/>>. **51.** Germany. Koordination Kurzdarmsyndrom. 2020. Homepage. Viewed 21 August 2020, <<https://www.koordination-kurzdarmsyndrom.de/>>. **52.** Italy. Un filo per la vita. 2020. Homepage. Viewed 21 August 2020, <<http://www.unfiloperlavita.it/>>. **53.** Netherlands. Crohn en Colitis Ulcerosa Vereniging Nederland. 2020. Homepage. Viewed 21 August 2020, <<https://www.crohn-colitis.nl/>>. **54.** Norway. NORILCO. 2020. Homepage. Viewed 21 August 2020, <<https://www.norilco.no/>>. **55.** Norway. Norsk Intravenøsforening. 2018. Homepage. Viewed 21 August 2020, <<https://www.nifono.no/>>. **56.** Norway. Landsforeningen mot fordøyelsessykdommer. 2020. Homepage. Viewed 21 August 2020, <<https://www.lmforgena.no/>>. **57.** Poland. Apetyt na Życie. 2020. Homepage. Viewed 21 August 2020, <<https://apetytnazycie.org/en/homepage-eng/>>. **58.** Slovenia. Društvo za kronično vnetno črevesno bolezen. 2020. Homepage. Viewed 21 August 2020, <<https://www.kvcb.si/>>. **59.** Slovenia. Invalidsko društvo Kengurujček Slovenije. 2017. Homepage. Viewed 21 August 2020, <<http://www.kengurujcek.si/>>. **60.** Spain. Asociación de niños, adultos y familias con fallo intestinal, nutrición parenteral y trasplante múltiple. 2020. Homepage. Viewed 21 August 2020, <<https://somasnupa.org/>>. **61.** Spain. Asociación valenciana de niños con síndrome de intestino corto y dependientes de nutrición parenteral. 2020. Homepage. Viewed 21 August 2020, <<https://www.solucionesong.org/long/asociacion-valenciana-de-ninos-con-sindrome-de-intestino-corto-y-dependientes-de-nutricion-parenteral-asvanc/10160/view>>. **62.** Sweden. Svenska HPN-Föreningen. 2020. Homepage. Viewed 21 August 2020, <<https://www.hpns.se/>>. **63.** Sweden. I.LCO. 2020. Homepage. Viewed 21 August 2020, <<https://www.ilco.nu/>>. **64.** Switzerland. Magendarmliga Schweiz. 2020. Homepage. Viewed 21 August 2020, <<https://www.gastromed.ch/>>. **65.** Switzerland. Crohn Colitis Schweiz. 2020. Homepage. Viewed 21 August 2020, <<https://www.crohn-colitis.ch/>>. **66.** United Kingdom. Patients on Intravenous and Naso-gastric Nutrition Treatment. 2020. Homepage. Viewed 21 August 2020, <<https://pinnt.com/About-Us.aspx>>. **67.** United Kingdom. Short Bowel Survivor & friends. 2020. Homepage. Viewed 21 August 2020, <<https://www.shortbowelsurvivor.co.uk/>>.

Disclaimers

Intended for a global audience (outside of the US/UK).

This project is initiated and funded by Takeda.

Copyright 2020 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.